S
Shengyan Hong
Researcher at Gdańsk Medical University
Publications - 2
Citations - 374
Shengyan Hong is an academic researcher from Gdańsk Medical University. The author has contributed to research in topics: Pemetrexed & Lung cancer. The author has an hindex of 2, co-authored 2 publications receiving 341 citations.
Papers
More filters
Journal ArticleDOI
Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.
Jacek Jassem,Rodryg Ramlau,Armando Santoro,Wolfgang Schuette,Assad Chemaissani,Shengyan Hong,J. Blatter,S. Adachi,Axel Hanauske,Christian Manegold +9 more
TL;DR: Second-line pemetrexed elicited significant tumor response and delayed disease progression compared with BSC alone in patients with advanced MPM, and Cox regression modeling suggested a trending survival benefit for patients who responded to first-line therapy.
Journal ArticleDOI
Phase III Study of Pemetrexed Plus Carboplatin Compared With Etoposide Plus Carboplatin in Chemotherapy-Naive Patients With Extensive-Stage Small-Cell Lung Cancer
Mark A. Socinski,Egbert F. Smit,Paul Lorigan,Kartik Konduri,Martin Reck,Aleksandra Szczesna,Johnetta Blakely,Piotr Serwatowski,Nina Karaseva,Tudor Ciuleanu,Jacek Jassem,Mircea Dediu,Shengyan Hong,Carla Visseren-Grul,Axel Hanauske,Coleman K. Obasaju,Susan C. Guba,Nick Thatcher +17 more
TL;DR: Pemetrexed-carboplatin is inferior for the treatment of ES-SCLC and Planned translational research and pharmacogenomic analyses of tumor and blood samples may help explain the study results and provide insight into new treatment strategies.